Aberrant activation of the phosphoinositide 3-kinase/alpha-serine/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway plays a key role in cancer development, making it an attractive therapeutic target. Here, MTOR is linked to cancer.